Advertisement
Screener

MUSTANG BIO, INC. (MBIO) Operating Cash Flow

2.8 / 5 stars · 68/120 Roast Me

MUSTANG BIO, INC. Operating Cash Flow

MUSTANG BIO, INC. (MBIO) reported Operating Cash Flow of -$1.98 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.

Financial Statements › Cash Flow › Operating Activities

us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-05

  • MUSTANG BIO, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$967.00K.
  • MUSTANG BIO, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$1.01M.
  • MUSTANG BIO, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$1.72M.
  • MUSTANG BIO, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$818.00K.
  • MUSTANG BIO, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$5.26M.
  • MUSTANG BIO, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$11.41M.
  • MUSTANG BIO, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$49.48M.
  • MUSTANG BIO, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$65.07M.
Period endNet Cash Provided by (Used in) Operating Activities 3 monthNet Cash Provided by (Used in) Operating Activities 6 monthNet Cash Provided by (Used in) Operating Activities 9 monthNet Cash Provided by (Used in) Operating Activities 10 monthNet Cash Provided by (Used in) Operating Activities 12 month
2026-06-30-$967.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05
-$1.98M
10-Q · filed 2026-08-05
-$3.69M
derived: sum of 3 quarters · filed 2026-08-05
-$4.51M
derived: sum of 4 quarters · filed 2026-08-05
2026-03-31-$1.01M
10-Q · filed 2026-05-05
-$2.73M
derived: sum of 2 quarters · filed 2026-05-05
-$3.54M
derived: sum of 3 quarters · filed 2026-05-05
-$4.88M
derived: sum of 4 quarters · filed 2026-08-05
2025-12-31-$1.72M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19
-$2.54M
derived: sum of 2 quarters · filed 2026-03-19
-$3.88M
derived: sum of 3 quarters · filed 2026-08-05
-$5.26M
10-K · filed 2026-03-19
2025-09-30-$818.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07
-$2.16M
derived: sum of 2 quarters · filed 2026-08-05
-$3.55M
10-Q · filed 2025-11-07
-$5.54M
derived: sum of 4 quarters · filed 2026-08-05
2025-06-30-$1.34M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05
-$2.73M
10-Q · filed 2026-08-05
-$4.72M
derived: sum of 3 quarters · filed 2026-08-05
-$6.48M
derived: sum of 4 quarters · filed 2026-08-05
2025-03-31-$1.39M
10-Q · filed 2026-05-05
-$3.39M
derived: sum of 2 quarters · filed 2026-05-05
-$5.14M
derived: sum of 3 quarters · filed 2026-05-05
-$7.48M
derived: sum of 4 quarters · filed 2026-05-05
2024-12-31-$2.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19
-$3.75M
derived: sum of 2 quarters · filed 2026-03-19
-$6.09M
derived: sum of 3 quarters · filed 2026-03-19
-$11.41M
10-K · filed 2026-03-19
2024-09-30-$1.76M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07
-$4.09M
derived: sum of 2 quarters · filed 2025-11-07
-$9.41M
10-Q · filed 2025-11-07
-$16.67M
derived: sum of 4 quarters · filed 2025-11-07
2024-06-30-$2.33M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08
-$7.66M
10-Q · filed 2025-08-08
-$14.91M
derived: sum of 3 quarters · filed 2025-08-08
-$26.93M
derived: sum of 4 quarters · filed 2025-08-08
2024-03-31-$5.32M
10-Q · filed 2025-05-14
-$12.57M
derived: sum of 2 quarters · filed 2025-05-14
-$24.60M
derived: sum of 3 quarters · filed 2025-05-14
-$36.99M
derived: sum of 4 quarters · filed 2025-05-14
2023-12-31-$7.25M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28
-$19.28M
derived: sum of 2 quarters · filed 2025-03-28
-$31.67M
derived: sum of 3 quarters · filed 2025-03-28
-$49.48M
10-K · filed 2025-03-28
2023-09-30-$12.02M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08
-$24.41M
derived: sum of 2 quarters · filed 2024-11-08
-$42.22M
10-Q · filed 2024-11-08
-$57.51M
derived: sum of 4 quarters · filed 2024-11-08
2023-06-30-$12.39M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13
-$30.20M
10-Q · filed 2024-08-13
-$45.49M
derived: sum of 3 quarters · filed 2024-08-13
-$61.40M
derived: sum of 4 quarters · filed 2024-08-13
2023-03-31-$17.81M
10-Q · filed 2024-05-15
-$33.10M
derived: sum of 2 quarters · filed 2024-05-15
-$49.01M
derived: sum of 3 quarters · filed 2024-05-15
-$66.58M
derived: sum of 4 quarters · filed 2024-05-15
2022-12-31-$15.29M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11
-$31.20M
derived: sum of 2 quarters · filed 2024-03-11
-$48.78M
derived: sum of 3 quarters · filed 2024-03-11
-$65.07M
10-K · filed 2024-03-11
2022-09-30-$15.91M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14
-$33.49M
derived: sum of 2 quarters · filed 2023-11-14
-$49.78M
10-Q · filed 2023-11-14
-$64.48M
derived: sum of 4 quarters · filed 2023-11-14
2022-06-30-$17.57M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14
-$33.86M
10-Q · filed 2023-08-14
-$48.57M
derived: sum of 3 quarters · filed 2023-08-14
-$59.86M
derived: sum of 4 quarters · filed 2023-08-14
2022-03-31-$16.29M
10-Q · filed 2023-05-12
-$30.99M
derived: sum of 2 quarters · filed 2023-05-12
-$42.28M
derived: sum of 3 quarters · filed 2023-05-12
-$54.38M
derived: sum of 4 quarters · filed 2023-05-12
2021-12-31-$14.70M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30
-$25.99M
derived: sum of 2 quarters · filed 2023-03-30
-$38.09M
derived: sum of 3 quarters · filed 2023-03-30
-$53.67M
10-K · filed 2023-03-30
2021-09-30-$11.29M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14
-$23.38M
derived: sum of 2 quarters · filed 2022-11-14
-$38.96M
10-Q · filed 2022-11-14
-$48.44M
derived: sum of 4 quarters · filed 2022-11-14
2021-06-30-$12.10M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11
-$27.68M
10-Q · filed 2022-08-11
-$37.15M
derived: sum of 3 quarters · filed 2022-08-11
-$47.27M
derived: sum of 4 quarters · filed 2022-08-11
2021-03-31-$15.58M
10-Q · filed 2022-05-12
-$25.05M
derived: sum of 2 quarters · filed 2022-05-12
-$35.18M
derived: sum of 3 quarters · filed 2022-05-12
-$42.75M
derived: sum of 4 quarters · filed 2022-05-12
2020-12-31-$9.47M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23
-$19.60M
derived: sum of 2 quarters · filed 2022-03-23
-$27.17M
derived: sum of 3 quarters · filed 2022-03-23
-$37.32M
10-K · filed 2022-03-23
2020-09-30-$10.12M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12
-$17.69M
derived: sum of 2 quarters · filed 2021-11-12
-$27.84M
10-Q · filed 2021-11-12
-$37.33M
derived: sum of 4 quarters · filed 2021-11-12
2020-06-30-$7.57M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16
-$17.72M
10-Q · filed 2021-08-16
-$27.21M
derived: sum of 3 quarters · filed 2021-08-16
-$36.04M
derived: sum of 4 quarters · filed 2021-08-16
2020-03-31-$10.15M
10-Q · filed 2021-05-14
-$19.64M
derived: sum of 2 quarters · filed 2021-05-14
-$28.47M
derived: sum of 3 quarters · filed 2021-05-14
-$37.25M
derived: sum of 4 quarters · filed 2021-05-14
2019-12-31-$9.49M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-24
-$18.32M
derived: sum of 2 quarters · filed 2021-03-24
-$27.10M
derived: sum of 3 quarters · filed 2021-03-24
-$33.58M
10-K · filed 2021-03-24
2019-09-30-$8.83M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06
-$17.61M
derived: sum of 2 quarters · filed 2020-11-06
-$24.09M
10-Q · filed 2020-11-06
-$30.61M
derived: sum of 4 quarters · filed 2020-11-06
2019-06-30-$8.78M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10
-$15.26M
10-Q · filed 2020-08-10
-$21.78M
derived: sum of 3 quarters · filed 2020-08-10
-$25.58M
derived: sum of 4 quarters · filed 2020-08-10
2019-03-31-$6.48M
10-Q · filed 2020-05-11
-$13.01M
derived: sum of 2 quarters · filed 2020-05-11
-$16.81M
derived: sum of 3 quarters · filed 2020-05-11
-$20.16M
derived: sum of 4 quarters · filed 2020-05-11
2018-12-31-$6.52M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16
-$10.32M
derived: sum of 2 quarters · filed 2020-03-16
-$13.68M
derived: sum of 3 quarters · filed 2020-03-16
-$19.24M
10-K · filed 2020-03-16
2018-09-30-$3.80M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12
-$7.16M
derived: sum of 2 quarters · filed 2019-11-12
-$12.72M
10-Q · filed 2019-11-12
-$17.89M
derived: sum of 4 quarters · filed 2019-11-12
2018-06-30-$3.36M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09
-$8.92M
10-Q · filed 2019-08-09
-$14.09M
derived: sum of 3 quarters · filed 2019-08-09
-$18.86M
derived: sum of 4 quarters · filed 2019-08-09
2018-03-31-$5.57M
10-Q · filed 2019-05-10
-$10.73M
derived: sum of 2 quarters · filed 2019-05-10
-$15.50M
derived: sum of 3 quarters · filed 2019-05-10
-$16.48M
derived: sum of 4 quarters · filed 2019-05-10
2017-12-31-$5.17M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18
-$9.94M
derived: sum of 2 quarters · filed 2019-03-18
-$10.91M
derived: sum of 3 quarters · filed 2019-03-18
-$12.95M
10-K · filed 2019-03-18
2017-09-30-$4.77M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13
-$5.75M
derived: sum of 2 quarters · filed 2018-11-13
-$7.78M
10-Q · filed 2018-11-13
-$10.04M
derived: sum of 4 quarters · filed 2018-11-13
2017-06-30-$974.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-13
-$3.01M
10-Q · filed 2018-08-13
-$5.27M
derived: sum of 3 quarters · filed 2018-08-13
2017-03-31-$2.04M
10-Q · filed 2018-05-14
-$4.30M
derived: sum of 2 quarters · filed 2018-05-14
2016-12-31-$2.26M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-29
-$4.13M
10-K · filed 2018-03-29
2016-09-30-$1.87M
10-Q · filed 2017-11-14
2015-12-31-$1.57M
10-K · filed 2018-03-29

Similar stocks

Stock NameCountryMarket CapPE Ratio
Vistagen Therapeutics, Inc. (VTGN)United States$0.013B-0.14
AEON Biopharma, Inc. (AEON)United States$0.013B-0.36
LISATA THERAPEUTICS, INC. (LSTA)United States$0.014B-2.13
Tempest Therapeutics, Inc. (TPST)United States$0.013B
Aspire Biopharma Holdings, Inc. (ASBP)United States$0.012B-0.60
BIOVIE INC. (BIVI)United States$0.012B
BullFrog AI Holdings, Inc. (BFRG)United States$0.014B
ADIAL PHARMACEUTICALS, INC. (ADIL)United States$0.012B
Vyome Holdings, Inc (HIND)United States$0.014B-1.38
Tvardi Therapeutics, Inc. (TVRD)United States$0.014B